Effect of Food and Formulation on the Pharmacokinetics, Safety, and Tolerability of GNS561 After One Single Dose (50 and 200mg) in Healthy Volunteers

Inclusion Criteria: * BMI will be between 18 (inclusive) and 26 kg/m² (inclusive). * Participants must be in good general health, with no significant medical history, have no clinically significant (CS) abnormalities on physical examination, vital signs, and 12-lead ECG at Screening and/or before administration of the first dose of study drug * Have a Fridericia's correction factor for QT (QTcF) ≤ 450 ms for male participants and ≤ 470 ms for female participants on 12-lead ECG * Women subjects of childbearing potential must have a negative serum/urine pregnancy test at screening and baseline * Women subjects of childbearing potential and male subjects must agree to use adequate highly effective contraception for the duration of study participation and up to 6 months following completion of therapy * Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. * Able to understand and provide written informed consent. Exclusion Criteria: * Pregnant or breast-feeding mothers * Known allergic reaction to quinolone derivatives (e.g., quinine, choloroquine, mefloquine) * Subjects with any clinically significant laboratory abnormality * History of QT prolongation (QTc ≥ 500 ms) or family history of long QT arrythmia or cardiac disease or bradycardia \< 50/mn or uncorrected hypokalemia * On going uncontrolled infection disease * History of pre-existing retinopathy or maculopathy * Participation in any investigational clinical investigation ≤ 4 weeks prior to first planned dose of GNS561 * Malabsorption issues (e.g., gastric bypass or gastrectomy patients), current or history significant gastrointestinal diseases * Patient with a mental or legal disability